Sanofi SA

SNW

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

stocks

Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026

Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks

Cheap ASX energy play boasts strong cash flows and balance sheet

Markets appear overly bearish on the company despite the company having attracting growth options.
stocks

Market overreacts to earnings miss from moated ASX retailer

Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,207.3032.70-0.35%
CAC 407,843.04126.65-1.59%
DAX 4024,273.1289.97-0.37%
Dow JONES (US)45,282.47349.27-0.77%
FTSE 1009,321.4012.200.13%
HKSE25,699.09130.82-0.51%
NASDAQ21,449.2947.24-0.22%
Nikkei 22542,394.40413.42-0.97%
NZX 50 Index12,957.98121.52-0.93%
S&P 5006,439.3227.59-0.43%
S&P/ASX 2008,935.6031.30-0.35%
SSE Composite Index3,879.054.51-0.12%

Market Movers